Business
Cellectis Announces 2026 Strategy and Catalysts
NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026. “2025 was a transformational year for Cellectis, as we transitioned to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel.
About this update from Cellectis S.a.
[{"type":"image","alt":"Cellectis Inc.","displaySize":"","headline":null,"caption":"Cellectis Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/U3etrkPEbdAWocW4KkNDeA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f68f579f9ddafa91af53fffe1d842d97","width":300,"height":119}},"lazy":false},{"type":"text","content":"NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities and key catalysts expected for 2026.","length":317,"tagName":"p"},{"type":"text","content":"“2025 was a transformational year for Cellectis, as we transitioned to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel.” said André Choulika, Ph.D., Chief Executive Officer of Cellectis. “As we enter 2026, we remain fully committed to executing our pivotal Phase 2 BALLI-01 trial for lasme-cel in ALL, with interim data expected in Q4, presenting the full Phase 1 data of the NATHALI-01 trial for eti-cel in NHL, and leveraging the momentum of our strategic partnership with AstraZeneca.”","length":551,"tagName":"p"},{"type":"text","content":"Allogeneic CAR-T Pipeline","length":25,"tagName":"p"},{"type":"text","content":"Lasme-cel in r/r B-ALL (BALLI-01)","length":33,"tagName":"p"},{"type":"text","content":"Following the initiation of the pivotal Phase 2 BALLI-01 clinical trial in October 2025, Cellectis expects to complete the first interim analysis in Q4 2026. This upcoming milestone (n=40) builds upon the encouraging Phase 1 clinical data presented at the Cellectis’ R&D Day, which highlighted:","length":298,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Strong Efficacy: 68% overall response rate (ORR) with lasme-cel Process 2 (n=22), 83% at the recommended Phase 2 dose (RP2D) (n=12) and 100% in the target Phase 2 population (n=9). 56% complete remission or complete remission with incomplete hematologic recovery (CR/CRi) rate with ~80% of these patients achieving m...